EyePoint (EYPT) expects its cash, cash equivalents, and marketable securities as of September 30, 2025, along with the net proceeds from the October equity financing, will enable the Company to fund operations into the fourth quarter of 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target raised to $33 from $28 at Mizuho
- EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint Pharmaceuticals Raises $141M in Public Offering
- EyePoint reports inducement grants under NASDAQ listing rule